Logo
A

AviadoBio

74 employees

At AviadoBio, we are relentlessly chasing cures by translating groundbreaking science and precision delivery into life-changing medicines for people living with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). With our deep understanding of the brain and our suite of proprietary gene therapy platforms and delivery technologies, we are working relentlessly to overcome the challenges of delivering the right drug to the right place. Our innovative, neuroanatomy-led approach is designed to maximize the therapeutic potential of gene therapy to halt or potentially reverse neurodegenerative diseases. The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.

Investor insights

Funding rounds participated in

$20M sweet spot round size

Investor type

Privately Held

Basic info

Industry

Biotechnology Research

Sectors

Biotechnology Research

Date founded

2019

Funding rounds raised

Total raised

$20M

from 1 investors over 1 rounds

A

AviadoBio raised $20M on November 8, 2024

Investors: Astellas Pharma

FAQ